No-Moat Intellia's Gene Editing Technology Looks Promising for Risk-Tolerant Investors
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...